These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11354383

  • 21. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain.
    Sumiyoshi T, Ichikawa J, Meltzer HY.
    Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT1A receptor antagonists.
    Yasunaga T, Kimura T, Naito R, Kontani T, Wanibuchi F, Yamashita H, Nomura T, Tsukamoto S, Yamaguchi T, Mase T.
    J Med Chem; 1998 Jul 16; 41(15):2765-78. PubMed ID: 9667967
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. 5-HT1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635.
    Sprouse J, Braselton J, Reynolds L.
    Ann N Y Acad Sci; 1998 Dec 15; 861():274-5. PubMed ID: 9928287
    [No Abstract] [Full Text] [Related]

  • 25. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain.
    Tilakaratne N, Friedman E.
    Eur J Pharmacol; 1996 Jun 27; 307(2):211-7. PubMed ID: 8832223
    [Abstract] [Full Text] [Related]

  • 26. Involvement of 5-HT1A receptors in the consolidation of learning in cognitively impaired rats.
    Meneses A, Terrón JA, Hong E.
    Ann N Y Acad Sci; 1998 Dec 15; 861():286-7. PubMed ID: 9928294
    [No Abstract] [Full Text] [Related]

  • 27. Development of a presynaptic 5-HT1A antagonist.
    Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, VanderMaelen CP, Yocca FD.
    Bioorg Med Chem Lett; 2003 Jan 20; 13(2):285-8. PubMed ID: 12482441
    [Abstract] [Full Text] [Related]

  • 28. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
    Trillat AC, Malagié I, Mathé-Allainmat M, Anmela MC, Jacquot C, Langlois M, Gardier AM.
    Eur J Pharmacol; 1998 Apr 17; 347(1):41-9. PubMed ID: 9650846
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS, Assié MB, Koek W.
    J Pharmacol Exp Ther; 1997 Aug 17; 282(2):747-59. PubMed ID: 9262338
    [Abstract] [Full Text] [Related]

  • 31. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system.
    Paluchowska MH, Duszyńska B, Kłodzińska A, Tatarczyńska E.
    Pol J Pharmacol; 2000 Aug 17; 52(3):209-16. PubMed ID: 11055578
    [Abstract] [Full Text] [Related]

  • 32. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
    Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ.
    Psychopharmacology (Berl); 2000 Sep 17; 152(1):55-66. PubMed ID: 11041316
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Structure-activity relationship studies of CNS agents, Part 31: Analogs of MP 3022 with a different number of nitrogen atoms in the heteroaromatic fragment--new 5-HT1A receptor ligands.
    Paluchowska MH, Dereń-Wesołek A, Mokrosz JL, Charakchieva-Minol S, Chojnacka-Wójcik E.
    Arch Pharm (Weinheim); 1996 Oct 17; 329(10):451-6. PubMed ID: 8933747
    [Abstract] [Full Text] [Related]

  • 35. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS, Kulkarni SK.
    Eur J Pharmacol; 2001 Sep 28; 428(1):81-6. PubMed ID: 11779040
    [Abstract] [Full Text] [Related]

  • 36. [On the Functional Cross-Talk between Brain 5-HT1A and 5-HT2A Receptors].
    Naumenko VS, Bazovkina DV, Kondaurova EM.
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2015 Sep 28; 65(2):240-7. PubMed ID: 26080602
    [Abstract] [Full Text] [Related]

  • 37. Two selective 5-HT1A receptor antagonists, WAY-100 635 and NDL-249, stimulate locomotion in rats acclimatised to their environment and alter their behaviour: a behavioural analysis.
    Jackson DM, Wallsten CE, Jerning E, Hu PS, Deveney AM.
    Psychopharmacology (Berl); 1998 Oct 28; 139(4):300-10. PubMed ID: 9809851
    [Abstract] [Full Text] [Related]

  • 38. Chronic administration of the cholesterol reducing drug gemfibrozil fails to alter 5-HT1A and 5-HT2A mediated receptor behaviours in rats.
    McCreary AC, Handley SL.
    J Psychopharmacol; 2000 Oct 28; 14(3):280-3. PubMed ID: 11106309
    [Abstract] [Full Text] [Related]

  • 39. Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors.
    Scandroglio A, Monferini E, Borsini F.
    Pharmacol Res; 2001 Feb 28; 43(2):179-83. PubMed ID: 11243720
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.